Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 8.2% in December

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 111,600 shares, an increase of 8.2% from the November 30th total of 103,100 shares. Based on an average daily volume of 118,500 shares, the short-interest ratio is currently 0.9 days. Approximately 0.7% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Oppenheimer restated an “outperform” rating and set a $11.00 price target (down previously from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th.

Institutional Investors Weigh In On Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Sphera Funds Management LTD. bought a new position in shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned 8.46% of Chemomab Therapeutics as of its most recent SEC filing. 46.05% of the stock is owned by hedge funds and other institutional investors.

Chemomab Therapeutics Stock Performance

Shares of NASDAQ:CMMB traded down $0.21 on Wednesday, hitting $1.81. The company’s stock had a trading volume of 125,418 shares, compared to its average volume of 176,470. Chemomab Therapeutics has a 12 month low of $0.46 and a 12 month high of $2.55. The stock’s 50-day moving average is $1.65 and its two-hundred day moving average is $1.46. The company has a market capitalization of $25.99 million, a price-to-earnings ratio of -1.81 and a beta of 0.66.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).